Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma

Journal of the Egyptian National Cancer Institute

Table 5 Relation between CD163 expression in both tumor nest and stroma and clinicopathologic characteristics

Variable	Total	CD163 in tumor nest			CD163 in tumor stroma
Variable	Total	Low N = 31 N (%)	High N = 29 N (%)	p	Low N = 32 N (%)	High N = 28 N (%)	p
Age (years) mean ± SD		52.68 ± 12.99	49.66 ± 9.99	0.319	49.41 ± 11.92	53.29 ± 11.15	0.200
Size
< 5 cm	39	21 (53.8)	18 (46.2)	0.645	25 (64.1)	14 (35.9)	0.023*
≥ 5 cm	21	10 (47.6)	11 (52.4)	0.645	7 (33.3)	14 (66.7)	0.023*
Grade
GII	32	22 (68.8)	10 (31.3)	0.005*	18 (56.3)	14 (43.7)	0.628
GIII	28	9 (32.1)	19 (67.9)	0.005*	14 (50)	14 (50)	0.628
Nodal metastasis
Negative	26	15 (57.7)	11 (42.3)	0.414	21 (80.8)	5 (19.2)	<0.001*
Positive	34	16 (47.1)	18 (52.9)	0.414	11 (32.4)	23 (67.6)	<0.001*
Staging
I	3	3 (100)	0 (0)	0.324	3 (100)	0 (0)	0.001*
II	32	16 (50)	16 (50)		22 (68.8)	10 (31.2)
III	25	12 (48)	13 (52)		7 (28)	18 (72)
Vascular invasion
Negative	22	13 (59.1)	9 (40.9)	0.381	16 (72.7)	6 (27.3)	0.022*
Positive	38	18 (47.4)	20 (52.6)	0.381	16 (42.1)	22 (57.9)	0.022*
ER
Negative	13	5 (38.5)	8 (61.5)	0.282	2 (15.4)	11 (84.6)	0.002*
Positive	47	26 (55.3)	21 (44.7)	0.282	30 (63.8)	17 (36.2)	0.002*
PR
Negative	26	13 (50)	13 (50)	0.821	12 (46.2)	14 (53.8)	0.330
Positive	34	18 (52.9)	16 (47.1)	0.821	20 (58.8)	14 (41.2)	0.330
Her2
Negative	41	25 (55.6)	20 (44.4)	0.296	21 (46.7)	24 (53.3)	0.084
Positive	19	6 (40)	9 (60)	0.296	11 (73.3)	4 (26.7)	0.084
Ki-67
≤ 14%	29	21 (72.4)	8 (27.6)	0.002*	17 (58.6)	12 (41.4)	0.427
> 14%	31	10 (32.3)	21 (67.7)	0.002*	15 (48.4)	16 (51.6)	0.427
Molecular subtypes
Luminal A	27	21 (77.8)	6 (22.2)	0.001*	15 (55.6)	12 (44.4)	0.017*
Luminal B	24	6 (25)	18 (75)		16 (66.7)	8 (33.3)
Triple negative	9	4 (44.4)	4 (55.6)		1 (11.1)	8 (88.9)